Search Results

You are looking at 51 - 60 of 543 items for

  • Abstract: Aging x
  • Abstract: Inflammation x
  • Abstract: Late effects of cancer treatment x
Clear All Modify Search
Thomas Reinehr Pediatric Endocrinology, Diabetes and Nutrition Medicine, Vestische Children’s Hospital, University of Witten/Herdecke, Datteln, Germany

Search for other papers by Thomas Reinehr in
Google Scholar
PubMed
Close
,
Martin Carlsson Endocrine Care, Pfizer Inc, New York, New York, USA

Search for other papers by Martin Carlsson in
Google Scholar
PubMed
Close
,
Dionisios Chrysis Division of Pediatric Endocrinology, University of Patras, Patras, Greece

Search for other papers by Dionisios Chrysis in
Google Scholar
PubMed
Close
, and
Cecilia Camacho-Hübner Endocrine Care, Pfizer Inc, New York, New York, USA

Search for other papers by Cecilia Camacho-Hübner in
Google Scholar
PubMed
Close

Background

The precision of adult height prediction by bone age determination in children with idiopathic growth hormone deficiency (IGHD) is unknown.

Methods

The near adult height (NAH) of patients with IGHD in the KIGS database was compared retrospectively to adult height prediction calculated by the Bayley–Pinneau (BP) prediction based on bone age by Greulich–Pyle (GP) in 315 children and based on the Tanner-Whitehouse 2 (TW2) method in 121 children. Multiple linear regression analyses adjusted for age at GH start, age at puberty, mean dose and years of of GH treatment, and maximum GH peak in stimulation test were calculated.

Results

The mean underestimation of adult height based on the BP method was at baseline 4.1 ± 0.7 cm in girls and 6.1 ± 0.6 cm in boys, at 1 year of GH treatment 2.5 ± 0.5 cm in girls and 0.9 ± 0.4 cm in boys, while at last bone age determination adult height was overestimated in mean by 0.4 ± 0.6 cm in girls and 3.8 ± 0.5 cm in boys. The mean underestimation of adult height based on the TW2 method was at baseline 5.3 ± 2.0 cm in girls and 7.9 ± 0.8 cm in boys, at 1 year of GH treatment adult height was overestimated in girls 0.1 ± 0.6 cm in girls and underestimated 4.1 ± 0.4 cm in boys, while at last bone age determination adult height was overestimated in mean by 3.1 ± 1.5 cm in girls and 3.6 ± 0.8 cm in boys.

Conclusions

Height prediction by BP and TW2 at onset of GH treatment underestimates adult height in prepubertal IGHD children, while in mean 6 years after onset of GH treatment these prediction methods overestimated adult height.

Open access
L Johnsen Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by L Johnsen in
Google Scholar
PubMed
Close
,
N B Lyckegaard Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by N B Lyckegaard in
Google Scholar
PubMed
Close
,
P Khanal Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by P Khanal in
Google Scholar
PubMed
Close
,
B Quistorff Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by B Quistorff in
Google Scholar
PubMed
Close
,
K Raun Diabetes and Obesity Pharmacology, Novo Nordisk A/S, Måløv, Denmark

Search for other papers by K Raun in
Google Scholar
PubMed
Close
, and
M O Nielsen Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by M O Nielsen in
Google Scholar
PubMed
Close

Objective

We aimed to test, whether fetal under- or overnutrition differentially program the thyroid axis with lasting effects on energy metabolism, and if early-life postnatal overnutrition modulates implications of prenatal programming.

Design

Twin-pregnant sheep (n = 36) were either adequately (NORM), under- (LOW; 50% of NORM) or overnourished (HIGH; 150% of energy and 110% of protein requirements) in the last-trimester of gestation. From 3 days-of-age to 6 months-of-age, twin lambs received a conventional (CONV) or an obesogenic, high-carbohydrate high-fat (HCHF) diet. Subgroups were slaughtered at 6-months-of-age. Remaining lambs were fed a low-fat diet until 2½ years-of-age (adulthood).

Methods

Serum hormone levels were determined at 6 months- and 2½ years-of-age. At 2½ years-of-age, feed intake capacity (intake over 4-h following 72-h fasting) was determined, and an intravenous thyroxine tolerance test (iTTT) was performed, including measurements of heart rate, rectal temperature and energy expenditure (EE).

Results

In the iTTT, the LOW and nutritionally mismatched NORM:HCHF and HIGH:CONV sheep increased serum T3, T3:T4 and T3:TSH less than NORM:CONV, whereas TSH was decreased less in HIGH, NORM:HCHF and LOW:HCHF. Early postnatal exposure to the HCHF diet decreased basal adult EE in NORM and HIGH, but not LOW, and increased adult feed intake capacity in NORM and LOW, but not HIGH.

Conclusions: The iTTT revealed a differential programming of central and peripheral HPT axis function in response to late fetal malnutrition and an early postnatal obesogenic diet, with long-term implications for adult HPT axis adaptability and associated consequences for adiposity risk.

Open access
Min Yang Graduate School, Beijing University of Chinese Medicine, Beijing, China
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Min Yang in
Google Scholar
PubMed
Close
,
Xiangling Deng Graduate School, Beijing University of Chinese Medicine, Beijing, China
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Xiangling Deng in
Google Scholar
PubMed
Close
,
Shunan Wang Graduate School, Beijing University of Chinese Medicine, Beijing, China
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Shunan Wang in
Google Scholar
PubMed
Close
,
Bo Zhou Graduate School, Beijing University of Chinese Medicine, Beijing, China
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Bo Zhou in
Google Scholar
PubMed
Close
,
Wenquan Niu Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Wenquan Niu in
Google Scholar
PubMed
Close
, and
Zhixin Zhang International Medical Services, China-Japan Friendship Hospital, Beijing, China
Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Zhixin Zhang in
Google Scholar
PubMed
Close

Objectives

We aimed to identify and characterize potential factors, both individually and jointly as a nomogram, associated with short stature and pre-shortness in Chinese preschool-aged children.

Methods

Total of 9501 children aged 3–6 years were recruited from 30 kindergartens in Beijing and Tangshan from September to December 2020 using a stratified random sampling method. Effect-size estimates are expressed as odds ratio (OR) and 95% CI.

Results

The prevalence of short stature and pre-shortness in preschool-aged children was 3.9% (n = 375) and 13.1% (n = 1616), respectively. Factors simultaneously associated with the significant risk for short stature, pre-shortness and both included BMI, paternal height, maternal height, birth weight, birth height, latter birth order (≥2) and less parental patience to children. Besides, breastfeeding duration (≥12 months) was exclusively associated with pre-shortness (OR, 95% CI, P: 1.16, 1.01 to 1.33, 0.037), and childhood obesity with both short stature (3.45, 2.62 to 4.54, <0.001) and short stature/pre-shortness (1.37, 1.15 to 1.64, <0.001). Modeling of significant factors in nomograms had descent prediction accuracies, with the C-index being 77.0, 70.1 and 71.2% for short stature, pre-shortness and both, respectively (all P < 0.001).

Conclusions

Our findings indicate the joint contribution of inherited characteristics, nutrition status from the uterus to childhood, and family psychological environment to short stature and pre-shortness in Chinese preschool-aged children. Further validation in other independent groups is warranted.

Open access
Petar Milovanovic Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Laboratory for Anthropology and Skeletal Biology, Institute of Anatomy, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Search for other papers by Petar Milovanovic in
Google Scholar
PubMed
Close
and
Björn Busse Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Search for other papers by Björn Busse in
Google Scholar
PubMed
Close

An increasing number of patients worldwide suffer from bone fractures that occur after low intensity trauma. Such fragility fractures are usually associated with advanced age and osteoporosis but also with long-term immobilization, corticosteroid therapy, diabetes mellitus, and other endocrine disorders. It is important to understand the skeletal origins of increased bone fragility in these conditions for preventive and therapeutic strategies to combat one of the most common health problems of the aged population. This review summarizes current knowledge pertaining to the phenomenon of micropetrosis (osteocyte lacunar mineralization). As an indicator of former osteocyte death, micropetrosis is more common in aged bone and osteoporotic bone. Considering that the number of mineralized osteocyte lacunae per bone area can distinguish healthy, untreated osteoporotic and bisphosphonate-treated osteoporotic patients, it could be regarded as a novel structural marker of impaired bone quality. Further research is needed to clarify the mechanism of lacunar mineralization and to explore whether it could be an additional target for preventing or treating bone fragility related to aging and various endocrine diseases.

Open access
Eva Olga Melin Diabetes Research Laboratory, Lund University, Lund, Sweden
Department of Research and Development, Region Kronoberg, Växjö, Sweden

Search for other papers by Eva Olga Melin in
Google Scholar
PubMed
Close
,
Magnus Hillman Diabetes Research Laboratory, Lund University, Lund, Sweden

Search for other papers by Magnus Hillman in
Google Scholar
PubMed
Close
, and
Mona Landin-Olsson Diabetes Research Laboratory, Lund University, Lund, Sweden
Department of Endocrinology, Skane University Hospital, Lund, Sweden

Search for other papers by Mona Landin-Olsson in
Google Scholar
PubMed
Close

Objective

To explore associations between high midnight salivary cortisol (MSC) secretion and high blood pressure (BP) in type 1 diabetes (T1D).

Methods

Cross-sectional study of 196 adult patients with T1D (54% men). Associations between high MSC (≥9.3 nmol/L) and high systolic BP (>130 mmHg), and high diastolic BP (>80 mmHg) were explored for all patients, users and non-users of antihypertensive drugs (AHD). Adjustments were performed for age, sex, diabetes-related variables, p-creatinine, smoking, physical inactivity, depression and medication.

Results

The prevalence of high MSC differed between patients with high and low systolic BP in all 196 patients: 39 vs 13% (P = 0.001); in 60 users of AHD: 37 vs 12% (P = 0.039), and in 136 non-users of AHD: 43 vs 13% (P = 0.012). Significant associations with high systolic BP were for all patients: physical inactivity (adjusted odds ratio (AOR) 6.5), high MSC (AOR 3.9), abdominal obesity (AOR 3.7), AHD (AOR 2.9), age (per year) (AOR 1.07), and p-creatinine (per µmol/L) (AOR 1.03); for 60 users of AHD: high MSC (AOR 4.1) and age (per year) (AOR 1.11); for 136 non-users of AHD: abdominal obesity (AOR 27.4), physical inactivity (AOR 14.7), male sex (AOR 9.0), smoking (AOR 7.9), and age (per year) (AOR 1.08). High MSC was not associated with high DBP.

Conclusions

In adult patients with T1D, high systolic BP was associated with physical inactivity, high MSC secretion, abdominal obesity, p-creatinine, age, and AHD, the latter indicating treatment failure.

Open access
Farzaneh Rohani Pediatric Growth and Development Research Center, Iran University of Medical Sciences, Tehran, Iran
Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Search for other papers by Farzaneh Rohani in
Google Scholar
PubMed
Close
,
Mohammad Reza Alai Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Search for other papers by Mohammad Reza Alai in
Google Scholar
PubMed
Close
,
Sedighe Moradi Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

Search for other papers by Sedighe Moradi in
Google Scholar
PubMed
Close
, and
Davoud Amirkashani Department of Pediatrics Endocrinology and Metabolism, Ali Asghar Children’s Hospital, Iran University of Medical Sciences, Tehran, Iran

Search for other papers by Davoud Amirkashani in
Google Scholar
PubMed
Close

Background

This study was conducted to find out whether boys with constitutional delay in growth and puberty (CDGP) could attain their target height and predicted adult height (PAH) in adulthood or not.

Methods

After measuring the height, weight, pubertal stage, parental height and bone age data of the patients at their first presentation were extracted from the files and their height and weight were measured at the end of the study, wrist X-Ray was performed in order to determine the bone age. PAH was calculated using Bayley–Pinneau method and target height was estimated by mid parental height. Final or near final heights of the patients were measured and compared with the target height and PAH.

Results

The mean age at presentation and the end of study was 15.2 ± 0.95, 20 ± 0.75 years respectively. Mean of bone age at the beginning of study was 12.97 ± 1 years and at the end of study were 17.6 ± 0.58 years. Mean of delayed bone age was 2.2 ± 0.82 years. Mean of the primary measured heights was 150.16 ± 7 cm (138–160 cm). Mean of final or near final heights was 165.7 ± 2.89 cm (161–170.5 cm). Final or near final heights in our subjects were smaller than either their PAH (165.7 ± 2.89 vs 170.7 ± 5.17) (P value <0.005) or target height (165.7 ± 2.89 vs 171.8 ± 4.65) (P value <0.0001).

Conclusion

Most patients with CDGP do not reach their target height or predicted adult height; they are usually shorter than their parents and general population. Such patients need to be followed up until they reach their final height and, in some cases, adjunctive medical treatment might be indicated.

Open access
Heike Hoyer-Kuhn Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Search for other papers by Heike Hoyer-Kuhn in
Google Scholar
PubMed
Close
,
Angela Huebner Department of Paediatrics, University Children’s Hospital Dresden, Dresden, Germany

Search for other papers by Angela Huebner in
Google Scholar
PubMed
Close
,
Anette Richter-Unruh University Children’s Hospital Bochum, Bochum, Nordrhein-Westfalen, Germany

Search for other papers by Anette Richter-Unruh in
Google Scholar
PubMed
Close
,
Markus Bettendorf University Children’s Hospital Heidelberg, Heidelberg, Germany

Search for other papers by Markus Bettendorf in
Google Scholar
PubMed
Close
,
Tilman Rohrer University Children’s Hospital Homburg, Homburg, Germany

Search for other papers by Tilman Rohrer in
Google Scholar
PubMed
Close
,
Klaus Kapelari University Children’s Hospital Innsbruck, Innsbruck, Austria

Search for other papers by Klaus Kapelari in
Google Scholar
PubMed
Close
,
Stefan Riedl Department of Pediatric, Medical University of Vienna, Vienna, Austria
St.Anna Kinderspital, Medical University of Vienna, Vienna, Austria

Search for other papers by Stefan Riedl in
Google Scholar
PubMed
Close
,
Klaus Mohnike Department of Biometrics, Otto von Guericke Universität Magdeburg, Magdeburg, Sachsen-Anhalt, Germany

Search for other papers by Klaus Mohnike in
Google Scholar
PubMed
Close
,
Helmuth-Günther Dörr University Children’s Hospital Erlangen, Erlangen, Germany

Search for other papers by Helmuth-Günther Dörr in
Google Scholar
PubMed
Close
,
Friedrich-Wilhelm Roehl Department of Biometrics, Otto von Guericke Universität Magdeburg, Magdeburg, Sachsen-Anhalt, Germany

Search for other papers by Friedrich-Wilhelm Roehl in
Google Scholar
PubMed
Close
,
Katharina Fink Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany

Search for other papers by Katharina Fink in
Google Scholar
PubMed
Close
,
Reinhard W Holl Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany

Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
Close
, and
Joachim Woelfle University Children’s Hospital Erlangen, Erlangen, Germany

Search for other papers by Joachim Woelfle in
Google Scholar
PubMed
Close

Objective

Treatment of classic congenital adrenal hyperplasia (CAH) is necessary to compensate for glucocorticoid/mineralocorticoid deficiencies and to suppress androgen excess. Hydrocortisone (HC) is preferred in growing children with classic CAH but recommendations regarding dosage/administration are inconsistent. The aim of this study was to evaluate HC dosing in children with CAH in relation to chronological age, sex, and phenotype based on a multicenter CAH registry.

Design

The CAH registry was initiated in 1997 by the AQUAPE in Germany. On December 31st 2018, data from 1571 patients were included.

Methods

A custom-made electronic health record software is used at the participating centers. Pseudonymized data are transferred for central analysis. Parameters were selected based on current guidelines. Descriptive analyses and linear regression models were implemented with SAS 9.4.

Results

We identified 1288 patients on exclusive treatment with hydrocortisone three times daily (604 boys; median age 7.2 years; 817 salt-wasting phenotype, 471 simple-virilizing phenotype). The mean (lower-upper quartiles) daily HC dose (mg/m² body surface area) was 19.4 (18.9–19.8) for patients <3 months (n = 329), 15.0 (14.6–15.3) for age ≥3–12 months (n = 463), 14.0 (13.7–14.3) for age 1–5.9 years (n = 745), 14.2 (14.0–14.5) for age 6 years to puberty entry (n = 669), and 14.9 (14.6–15.2) during puberty to 18 years (n = 801). Fludrocortisone was administered in 74.1% of patients with a median daily dosage of 88.8 µg.

Conclusion

Our analyses showed that still a high proportion of children are treated with HC doses higher than recommended. This evaluation provides comprehensive information on nationwide hydrocortisone substitution dosages in children with CAH underlining the benefit of systematic data within a registry to assess daily practice.

Open access
Dorte Glintborg Department of Endocrinology, Odense University Hospital, Odense, Denmark
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Close
,
Katrine Hass Rubin Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark

Search for other papers by Katrine Hass Rubin in
Google Scholar
PubMed
Close
,
Simon Bang Mohr Kristensen Open Patient Data Explorative Network, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark

Search for other papers by Simon Bang Mohr Kristensen in
Google Scholar
PubMed
Close
,
Øjvind Lidegaard Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Øjvind Lidegaard in
Google Scholar
PubMed
Close
,
Guy T’Sjoen Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Gent, Belgium

Search for other papers by Guy T’Sjoen in
Google Scholar
PubMed
Close
,
Aisa Burgwal Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Gent, Belgium

Search for other papers by Aisa Burgwal in
Google Scholar
PubMed
Close
,
Malene Hilden Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Centre for Gender Identity, Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Malene Hilden in
Google Scholar
PubMed
Close
, and
Marianne Skovsager Andersen Department of Endocrinology, Odense University Hospital, Odense, Denmark
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Close

Background

Gender dysphoria could be associated with low socioeconomic status (SES). SES could be modified by age, ethnic background, and medical morbidity.

Aim

To determine SES in a national study population including transgender persons in Denmark.

Methods

National register-based cohort study in Danish transgender persons and age-matched controls. The transgender study cohort included persons with ICD-10 diagnosis code of 'gender identity disorder' and/or persons with legal sex change and persons who fulfiled the inclusion criteria during 2000–2018. The main outcome measure was SES including personal income, occupational status, and education.

Results

The cohort included 2770 transgender persons and 27,700 controls. In the transgender study cohort, 1437 were assigned male at birth (AMAB), median age (interquartile range, IQR) 26.0 (17.3) years, and 1333 were assigned female at birth (AFAB), median age 22.5 (10.3) years. Adjusting for age and sex, the relative risk ratio (RRR) of low vs high personal income was 5.6 (95% CI: 4.9; 6.3) in transgender persons compared to controls. The RRR of low vs high income was 6.9 (5.8; 8.3) in persons AMAB compared to control males and 4.7 (3.9; 5.6) in persons AFAB compared to control females. The RRR of low vs high income was 3.7 (3.2; 4.3) in transgender persons of Danish origin compared to controls. The Charlson comorbidity index was comparable in transgender persons vs controls.

Conclusions

Being transgender was negatively associated with SES. In transgender persons, the risk of low vs high income could be more pronounced in transgender persons of foreign origin.

Open access
Sakina Kherra CHU Parnet Hopital, Algiers, Algeria

Search for other papers by Sakina Kherra in
Google Scholar
PubMed
Close
,
Wendy Forsyth Paterson Royal Hospital for Sick Children, Yorkhill, Glasgow, UK

Search for other papers by Wendy Forsyth Paterson in
Google Scholar
PubMed
Close
,
Filiz Mine Cizmecioglu Paediatric Endocrinology and Diabetes Department, Kocaeli University, Kocaeli, Turkey

Search for other papers by Filiz Mine Cizmecioglu in
Google Scholar
PubMed
Close
,
Jeremy Huw Jones Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UK

Search for other papers by Jeremy Huw Jones in
Google Scholar
PubMed
Close
,
Mariam Kourime Abderrahim Harouchi Hôpital, Casablanca, Morocco

Search for other papers by Mariam Kourime in
Google Scholar
PubMed
Close
,
Heba Hassan Elsedfy Pediatrics Department, Ain Shams University, Cairo, Egypt

Search for other papers by Heba Hassan Elsedfy in
Google Scholar
PubMed
Close
,
Sameh Tawfik Department of Pediatrics, Maadi Hospital, Cairo, Egypt

Search for other papers by Sameh Tawfik in
Google Scholar
PubMed
Close
,
Andreas Kyriakou Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UK

Search for other papers by Andreas Kyriakou in
Google Scholar
PubMed
Close
,
Mohamad Guftar Shaikh Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UK

Search for other papers by Mohamad Guftar Shaikh in
Google Scholar
PubMed
Close
, and
Malcolm David Cairns Donaldson Section of Child Health, Glasgow University School of Medicine, Glasgow, UK

Search for other papers by Malcolm David Cairns Donaldson in
Google Scholar
PubMed
Close

Background

Hypogonadism is a key feature of Prader–Willi syndrome (PWS) but clear strategies for hormone replacement are lacking.

Objective

To evaluate the gonadal status and outcome in patients attending a Scottish PWS clinic from 1991 to 2019.

Methods

In 93 (35F:56M) patients, median follow-up 11.2 years, gonadal and pubertal status were assessed clinically. Pelvic ultrasound findings and basal/stimulated gonadotrophins were compared with age-matched controls.

Results

Females:of 22 patients aged > 11, 9 had reached B4–5, while 5 were still at B2–3, and 6 remained prepubertal. Eight patients experienced menarche aged 9.8–21.4 years, none with a normal cycle. Uterine length and ovarian volumes were normal but uterine configuration remained immature, with low follicular counts. Gonadotrophins were unremarkable, serum oestradiol 129 (70–520) pmol/L. Only 5 patients received oestrogen replacement. Males:fifty-four (96%) patients were cryptorchid (9 unilateral). Weekly hCG injections resulted in unilateral/bilateral descent in 2/1 of 25 patients. Of 37 boys aged > 11, 14 (9 with failed/untreated bilateral cryptorchidism) failed to progress beyond G1, 15 arrested at G2–3 (testes 3–10 mL), and 8 reached G4–5. Gonadotrophins were unremarkable except in boys at G2–5 in whom FSH was elevated: 12.3/27.3 vs 3.25/6.26 U/L in controls (P < 0.001). In males aged > 13, testosterone was 3.1 (0.5–8.4) nmol/L. Androgen therapy, given from 13.5 to 29.2 years, was stopped in 4/24 patients owing to behavioural problems.

Conclusion

Despite invariable hypogonadism, few females and only half the males with PWS in this study received hormone replacement. Double-blind placebo-controlled crossover trials of sex steroids are required to address unproven behavioural concerns.

Open access
Jose M Garcia GRECC VA Puget Sound HCS/University of Washington, Seattle, Washington, USA

Search for other papers by Jose M Garcia in
Google Scholar
PubMed
Close
,
Beverly M K Biller Massachusetts General Hospital, Neuroendocrine Unit, Boston, Massachusetts, USA

Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Close
,
Márta Korbonits Barts and the London School of Medicine, Queen Mary University of London, Endocrinology, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close
,
Vera Popovic University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Vera Popovic in
Google Scholar
PubMed
Close
,
Anton Luger Division of Endocrinology and Metabolism, Medical University, General Hospital, Vienna, Austria

Search for other papers by Anton Luger in
Google Scholar
PubMed
Close
,
Christian J Strasburger Charité-Universitätsmedizin, Clinical Endocrinology CCM, Berlin, Germany

Search for other papers by Christian J Strasburger in
Google Scholar
PubMed
Close
,
Philippe Chanson Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, and Université Paris-Saclay, Univ. Paris-Sud, Inserm, Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique, Le Kremlin-Bicêtre, France

Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Close
,
Ronald Swerdloff The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA

Search for other papers by Ronald Swerdloff in
Google Scholar
PubMed
Close
,
Christina Wang The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA

Search for other papers by Christina Wang in
Google Scholar
PubMed
Close
,
Rosa Rosanna Fleming Strongbridge Biopharma, Trevose, Pennsylvania, USA

Search for other papers by Rosa Rosanna Fleming in
Google Scholar
PubMed
Close
,
Fredric Cohen Strongbridge Biopharma, Trevose, Pennsylvania, USA

Search for other papers by Fredric Cohen in
Google Scholar
PubMed
Close
,
Nicola Ammer Aeterna Zentaris GmbH, Frankfurt, Hessen, Germany

Search for other papers by Nicola Ammer in
Google Scholar
PubMed
Close
,
Gilbert Mueller Aeterna Zentaris GmbH, Frankfurt, Hessen, Germany

Search for other papers by Gilbert Mueller in
Google Scholar
PubMed
Close
,
Nicky Kelepouris Novo Nordisk Inc., Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Close
,
Frank Strobl Novo Nordisk Inc., Plainsboro, New Jersey, USA

Search for other papers by Frank Strobl in
Google Scholar
PubMed
Close
,
Vlady Ostrow Novo Nordisk Inc., Plainsboro, New Jersey, USA

Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Close
, and
Kevin C J Yuen University of Arizona College of Medicine and Creighton School of Medicine, Barrow Pituitary Center, Barrow Neurological Institute, Phoenix, Arizona, USA

Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Close

Abstract

Objective

The macimorelin test is approved for the diagnosis of adult growth hormone deficiency (AGHD) based on its efficacy vs the insulin tolerance test (ITT). Macimorelin has a significant advantage over ITT in avoiding hypoglycemia. Analyses were conducted to determine whether macimorelin performance is affected by age, BMI, or sex, and evaluate its performance vs ITT over a range of GH cutpoints.

Design

Post hoc analyses of data from a previous randomized phase 3 study included participants aged 18–66 years with BMI <37 kg/m2 and high (Group A), intermediate (Group B), or low (Group C) likelihood for AGHD based on pituitary history, and matched controls (Group D).

Methods

Probability of AGHD was estimated using unadjusted, age-adjusted, BMI-adjusted, and sex-adjusted logistic models. Area under the curve (AUC) of the estimated receiver operating characteristic (ROC) curve (range, 0–1; 1 = perfect) was compared for adjusted vs unadjusted models. Separate analyses evaluated agreement, sensitivity, and specificity for macimorelin and ITT using cutpoints of 2.8, 4.0, 5.1, and 6.5 ng/mL.

Results

For participants in Group A (n = 41) and Group D (n = 29), unadjusted, age-adjusted, BMI-adjusted, and sex-adjusted models had ROC AUCs (95% CIs) of 0.9924 (0.9807–1), 0.9924 (0.9807–1), 0.9916 (0.9786–1), and 0.9950 (0.9861–1), respectively.

Conclusions

Macimorelin performance was not meaningfully affected by age, BMI, or sex, indicating robustness for AGHD diagnosis. Of the 4 GH cutpoints evaluated, the cutpoint of 5.1 ng/mL provided maximal specificity (96%) and high sensitivity (92%) and was in good overall agreement with the ITT at the same cutpoint (87%).

Open access